Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Rhea-AI Summary
Lyell Immunopharma (Nasdaq: LYEL) announced that senior management will join a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 1:30 p.m. ET.
A live webcast and replay will be available in the Investors section of Lyell’s website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – LYEL
On the day this news was published, LYEL declined 3.92%, reflecting a moderate negative market reaction. Argus tracked a trough of -15.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $319.21M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 12 | Clinical data update | Neutral | -2.0% | Updated safety and translational data for ronde-cel in large B-cell lymphoma. |
| Jun 08 | Trial design change | Neutral | +2.8% | Phase 1 LYL273 trial amended to Phase 1/2 with expanded patient cohorts. |
| Jun 04 | Conference presentation | Neutral | -8.3% | Planned Phase 1/2 ronde-cel safety and translational data presentations at EHA 2026. |
| Jun 01 | Investor conference | Neutral | -1.0% | Participation in Goldman Sachs Global Healthcare Conference with fireside chat webcast. |
| May 12 | Investor outreach | Neutral | +0.3% | Participation in two May oncology-focused investor conferences with webcasts. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news and clinical updates have produced mixed single-digit gains and losses, with one larger downside move after data-related headlines.
Regulatory & Risk Context
Short interest is at a moderate level, which can contribute to elevated volatility and the potential for short-covering moves if sentiment shifts.
An effective S-3 shelf allows resale of previously issued shares by selling stockholders, with the filing stating Lyell itself will not receive proceeds from these sales.
Key Terms
car t-cell therapies medical
chimeric antigen receptor medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 1:30 pm Eastern Time.
A live webcast of the fireside chat and subsequent replay can be accessed through the Investors section of the Company’s website at www.lyell.com.
About Lyell Immunopharma, Inc.
Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T-cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. LyFE has commercial launch capability and is expected to have the capacity to manufacture more than 1,200 CAR T-cell doses per year. To learn more, please visit www.lyell.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell management’s planned participation at an investor conference; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 6, 2026. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Contact:
Pablo Fenton
Associate Director, Investor Relations and Corporate Communications
pfenton@lyell.com
